110 related articles for article (PubMed ID: 10697522)
1. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line.
Asada N; Tsuchiya H; Tomita K
Anticancer Res; 1999; 19(6B):5131-7. PubMed ID: 10697522
[TBL] [Abstract][Full Text] [Related]
2. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
[TBL] [Abstract][Full Text] [Related]
3. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma.
Tsuchiya H; Mori Y; Ueda Y; Okada G; Tomita K
Anticancer Res; 2000; 20(1A):235-42. PubMed ID: 10769661
[TBL] [Abstract][Full Text] [Related]
4. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
5. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line.
Siddik ZH; Mims B; Lozano G; Thai G
Cancer Res; 1998 Feb; 58(4):698-703. PubMed ID: 9485023
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line.
Asada N; Tsuchiya H; Ueda Y; Tomita K
Anticancer Res; 1998; 18(3A):1765-8. PubMed ID: 9673402
[TBL] [Abstract][Full Text] [Related]
7. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
8. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel genes involved in the synergistic antitumor effect of caffeine in osteosarcoma cells using cDNA macroarray.
Ii S; Ueda Y; Shimazaki M; Katsuta S; Takazawa K; Kanazawa Y; Tomita K; Tsuchiya H
Anticancer Res; 2008; 28(2A):645-53. PubMed ID: 18507003
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.
Benassi MS; Chiechi A; Ponticelli F; Pazzaglia L; Gamberi G; Zanella L; Manara MC; Perego P; Ferrari S; Picci P
Cancer Lett; 2007 Jun; 250(2):194-205. PubMed ID: 17113707
[TBL] [Abstract][Full Text] [Related]
11. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
Chang FL; Ling YF; Lai MD
Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
[TBL] [Abstract][Full Text] [Related]
12. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.
García-Castellano JM; Villanueva A; Healey JH; Sowers R; Cordon-Cardo C; Huvos A; Bertino JR; Meyers P; Gorlick R
Clin Cancer Res; 2002 Mar; 8(3):782-7. PubMed ID: 11895909
[TBL] [Abstract][Full Text] [Related]
13. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.
Avery-Kiejda KA; Zhang XD; Adams LJ; Scott RJ; Vojtesek B; Lane DP; Hersey P
Clin Cancer Res; 2008 Mar; 14(6):1659-68. PubMed ID: 18310316
[TBL] [Abstract][Full Text] [Related]
14. Codominance of cisplatin resistance in somatic cell hybrids.
Ying YL; Shen DW; Liang XJ; Gottesman MM
J Cell Physiol; 2003 Jul; 196(1):63-9. PubMed ID: 12767041
[TBL] [Abstract][Full Text] [Related]
15. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
16. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation.
Houldsworth J; Xiao H; Murty VV; Chen W; Ray B; Reuter VE; Bosl GJ; Chaganti RS
Oncogene; 1998 May; 16(18):2345-9. PubMed ID: 9620551
[TBL] [Abstract][Full Text] [Related]
17. [Establishment of a cisplatin-multidrug resistance cell line of human osteosarcoma].
Zhang WT; Tu CQ; Liu Y; Li SF
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):262-5. PubMed ID: 16608090
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation.
Shono T; Tofilon PJ; Schaefer TS; Parikh D; Liu TJ; Lang FF
Cancer Res; 2002 Feb; 62(4):1069-76. PubMed ID: 11861384
[TBL] [Abstract][Full Text] [Related]
19. p53 gene gets altered by various mechanisms: studies in childhood sarcomas and retinoblastoma.
Ghule P; Kadam PA; Jambhekar N; Bamne M; Pai S; Nair C; Banavali S; Puri A; Agarwal M
Med Sci Monit; 2006 Dec; 12(12):BR385-396. PubMed ID: 17136003
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]